Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A mutational signature in gastric cancer suggests therapeutic strategies.

Nature communications - 29 Oct 2015

Alexandrov Ludmil B, Nik-Zainal Serena, Siu Hoi Cheong, Leung Suet Yi, Stratton Michael R

Abstract excerpt

Targeting defects in the DNA repair machinery of neoplastic cells, for example, those due to inactivating BRCA1 and/or BRCA2 mutations, has been used for developing new therapies in certain types of breast, ovarian and pancreatic cancers. Recently, a mutational signature was associated with failure of double-strand DNA break repair by homologous recombination based on its high mutational burden in samples...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to DNA Breaks

Share to DNA Repair

Share to Neoplasms

Share to Pancreatic Neoplasms

Share to Stomach Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 26511885
DOI: 10.1038/ncomms9683
PMCID: PMC4918743

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A mutational signature in gastric cancer suggests therapeutic strategies.PMID 26511885Read ↗

BRCA2 Germline Mutations Identify Gastric Cancers Responsive to PARP InhibitorsSemantic proximity Read ↗

Diagnostic tool to identify and treat DNA repair deficient gastroesophageal adenocarcinomasSemantic proximity Read ↗

Advancements and Obstacles of PARP Inhibitors in Gastric CancerSemantic proximity Read ↗

DNA Damage Repair and Current Therapeutic Approaches in Gastric Cancer: A Comprehensive ReviewSemantic proximity Read ↗

Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targetingSemantic proximity Read ↗

Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy durationSemantic proximity Read ↗

BReast CAncer (BRCA) gene mutations as an emerging biomarker for the treatment of gastrointestinal malignancies.Semantic proximity Read ↗

Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for TherapySemantic proximity Read ↗

Core Homologous Recombination Mutations and Improved Survival in Nonpancreatic GI Cancers.Semantic proximity Read ↗

BRCA-Mutated Pancreatic Cancer: From Discovery to Novel Treatment ParadigmsSemantic proximity Read ↗

Utility of Homologous Recombination Deficiency Biomarkers Across Cancer TypesSemantic proximity Read ↗

Landscape of homologous recombination deficiency in gastric cancer and clinical implications for first-line chemotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.